Agilent Technologies (NYSE:A) gapped down before the market opened on Tuesday . The stock had previously closed at $69.75, but opened at $68.07. Agilent Technologies shares last traded at $66.64, with a volume of 3548027 shares.
A has been the subject of a number of research reports. Evercore ISI initiated coverage on Agilent Technologies in a report on Wednesday, January 3rd. They set an “outperform” rating and a $75.00 target price for the company. Barclays reaffirmed a “buy” rating and set a $74.00 target price on shares of Agilent Technologies in a report on Monday, January 8th. Robert W. Baird reaffirmed a “buy” rating and set a $76.00 target price on shares of Agilent Technologies in a report on Thursday, January 18th. JPMorgan Chase lifted their target price on Agilent Technologies from $75.00 to $80.00 and gave the stock an “overweight” rating in a report on Thursday, February 15th. Finally, ValuEngine raised Agilent Technologies from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Three research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $72.20.
The company has a quick ratio of 2.78, a current ratio of 3.23 and a debt-to-equity ratio of 0.40. The stock has a market cap of $21,783.26, a price-to-earnings ratio of 28.24, a P/E/G ratio of 2.32 and a beta of 1.31.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 25th. Investors of record on Tuesday, April 3rd will be given a dividend of $0.149 per share. This represents a $0.60 annualized dividend and a yield of 0.89%. The ex-dividend date is Monday, April 2nd. Agilent Technologies’s dividend payout ratio is currently 25.42%.
In other news, Director Heidi Fields sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $68.09, for a total value of $340,450.00. Following the completion of the sale, the director now directly owns 57,563 shares in the company, valued at $3,919,464.67. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael R. Mcmullen sold 21,850 shares of the business’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $75.00, for a total value of $1,638,750.00. Following the completion of the sale, the chief executive officer now owns 324,687 shares of the company’s stock, valued at $24,351,525. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,550 shares of company stock valued at $3,225,202.
Institutional investors have recently bought and sold shares of the company. Leucadia National Corp purchased a new stake in shares of Agilent Technologies during the fourth quarter worth approximately $1,647,000. State of Alaska Department of Revenue increased its position in shares of Agilent Technologies by 190.2% during the fourth quarter. State of Alaska Department of Revenue now owns 57,154 shares of the medical research company’s stock worth $3,826,000 after purchasing an additional 37,460 shares in the last quarter. BlackRock Inc. increased its position in shares of Agilent Technologies by 8.1% during the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after purchasing an additional 1,912,186 shares in the last quarter. Rhumbline Advisers increased its position in shares of Agilent Technologies by 1.7% during the fourth quarter. Rhumbline Advisers now owns 558,724 shares of the medical research company’s stock worth $37,418,000 after purchasing an additional 9,438 shares in the last quarter. Finally, Sciencast Management LP increased its position in shares of Agilent Technologies by 30.9% during the fourth quarter. Sciencast Management LP now owns 18,148 shares of the medical research company’s stock worth $1,326,000 after purchasing an additional 4,279 shares in the last quarter.
Agilent Technologies Company Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.